ReviewMedical oncology (Northwood, London, England)2017
The role of RNA-binding protein tristetraprolin in cancer and immunity.
Review in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- ELAV/Hu RNA-binding protein family: key regulators in neurological disorders, cancer, and other diseases.RNA biology · 2025Review
- Quantitative modeling of mRNA degradation reveals tempo-dependent mRNA clearance in early embryos.Nucleic acids research · 2025Article
- Review
- ZFP36 loss-mediated BARX1 stabilization promotes malignant phenotypes by transactivating master oncogenes in NSCLC.Cell death & disease · 2023Article
- RNA binding protein: coordinated expression between the nuclear and mitochondrial genomes in tumors.Journal of translational medicine · 2023Review
- Differential expression of Dusp1 and immediate early response genes in the hippocampus of rats, subjected to forced swim test.Scientific reports · 2023Article
- Tristetraprolin promotes survival of mammary progenitor cells by restraining TNFα levels.Frontiers in cell and developmental biology · 2023Article
- MAPKAPK2-centric transcriptome profiling reveals its major role in governing molecular crosstalk of IGFBP2, MUC4, and PRKAR2B during HNSCC pathogenesis.Computational and structural biotechnology journal · 2023Article
- Snapshots of nascent RNA reveal cell- and stimulus-specific responses to acute kidney injury.JCI insight · 2022Article
- Nicotine-mediated OTUD3 downregulation inhibits VEGF-C mRNA decay to promote lymphatic metastasis of human esophageal cancer.Nature communications · 2021Article
- Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.Molecular cancer · 2021Article
- Icariin, an Up-and-Coming Bioactive Compound Against Neurological Diseases: Network Pharmacology-Based Study and Literature Review.Drug design, development and therapy · 2021Review
- Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to Malignancy.Cellular and molecular gastroenterology and hepatology · 2021Article
- Tumor suppressing effects of tristetraprolin and its small double-stranded RNAs in bladder cancer.Cancer medicine · 2021Article
- Tristetraprolin, a Potential Safeguard Against Carcinoma: Role in the Tumor Microenvironment.Frontiers in oncology · 2021Review
- Tristetraprolin Gene Single-Nucleotide Polymorphisms and mRNA Level in Patients With Rheumatoid Arthritis.Frontiers in pharmacology · 2021Article
- Quantitative and time-resolved miRNA pattern of early human T cell activation.Nucleic acids research · 2020Article
- Embryonal tumors with multi-layered rosettes: a disease of dysregulated miRNAs.Journal of neuro-oncology · 2020Review
- PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1.Journal of cellular and molecular medicine · 2020Article
- NRF1-enhanced miR-4458 alleviates cardiac hypertrophy through releasing TTP-inhibited TFAM.In vitro cellular & developmental biology. Animal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
RNA-binding protein tristetraprolin (TTP) plays a fundamental role in various physiological and pathological processes including differentiation, reprogramming, metabolism, proliferation, pluripotency, tumorigenesis and immunity. Due to its ability to bind and target ARE-containing mRNAs for rapid degradation, TTP down-regulates the expression of a mass of critical genes, thereby functioning as cancer suppressor gene. The loss of TTP has been reported in several human cancers and is relevant to poor prognosis. Recent research shows that TTP also has an emerging significant role in immunity. The aim of this paper is to provide an overview of various roles of TTP in human cancers and immunity. We summarize TTP deficiency in several cancers and discuss that the lack of TTP can influence tumor progression at different aspects such as promoting cancer cell proliferation; accelerating cell cycle; improving survivability and resisting cell death; inducing angiogenesis; activating invasion and metastasis; inducing epithelial-mesenchymal transition; and deregulating cellular energetics. We also pay attention to novel understanding of the relationship between TTP and immunity. Finally, due to its vital role, the disorder of TTP in both cancer and immune cells receives increasing attention and we overview current thinking about regulatory mechanisms of TTP itself expression. This knowledge may contribute to TTP becoming a diagnostic marker for cancer or immune-related diseases and a possible therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.